Vocimagene amiretrorepvec/extended release flucytosine: Phase II/III started

Tocagen began an open-label, U.S. Phase II/III trial to evaluate Toca 511 given on day 1 after resection followed by oral Toca FC vs. standard of care in about 170 patients with first or second recurr...